Eclipse Surgical Technologies.
This article was originally published in The Gray Sheet
Independent data and safety monitoring committee determines that the firm will not need to enroll additional patients in its clinical trial for transmyocardial revascularization performed in conjunction with coronary artery bypass graft surgery. Data show "eight times fewer early deaths" in the TMR/bypass group when compared to bypass surgery alone, the firm claims. Eclipse, which plans to submit either a premarket approval application or PMA supplement for use of its holmium laser for use in conjunction with bypass surgery, is "seeking the FDA's guidance on how to proceed." A pending PMA for its laser as sole treatment for patients believed to have no surgical option was submitted in July 1997 ("The Gray Sheet" July 14, In Brief)...
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.